Search results
Results from the Tech24 Deals Content Network
Moderna has struggled to maintain Wall Street's attention on its pipeline as it recovers from the COVID vaccine highs of 2022, when sales topped $19 billion. But CEO Stéphane Bancel told Yahoo ...
August 1, 2024 at 2:31 PM. Moderna ( MRNA) shares slid more than 20% Thursday after the company slashed its sales guidance for 2024, largely because of a lack of new COVID-19 vaccine orders from ...
Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 billion as of the end of the first quarter -- to fund its programs despite a ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...
Moderna president Stephen Hoge knows investors are waiting to see the company grow in a big way and regain the momentum lost following outsized COVID-19 vaccine revenues. "What we're kind of ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...
Moderna Current Valuation and Performance. Moderna stock sits at $146.36 per share as of Feb. 17, 2022. Depending on which analyst you believe, you should expect either a loss of 42% or gains of ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...